by Bill Snyder, Vanderbilt University Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern. The findings, published in the journal Cell Host & Microbe, could lead to potential broad-based therapies or a vaccine to...
Tag: <span>antibodies</span>
Post
Some severe COVID-19 cases linked to genetic mutations or antibodies that attack the body
by Howard Hughes Medical Institute Infection with the novel coronavirus (gold spheres) can cause a range of symptoms. Some people with severe cases of COVID-19 have genetic mutations in key immunity genes or antibodies that attack the immune system. Credit: NIAID People infected by the novel coronavirus can have symptoms that range from mild to deadly....
Post
Dartmouth-led team engineers new treatment for drug-resistant bacterial infections
THAYER SCHOOL OF ENGINEERING AT DARTMOUTH A MOLECULAR MODEL OF THE F12 BIOTHERAPY SHOWS THE FOLD OF ITS POLYPEPTIDE BACKBONE. RESIDUAL T CELL EPITOPES ARE MAPPED ONTO THE STRUCTURE AND COLORED FROM WHITE (NO EPITOPES). The Centers for Disease Control and Prevention (CDC) has prioritized finding effective treatment of Methicillin-resistant Staphylococcus aureus (MRSA), one of...
Post
University of Minnesota research team studies neutralizing monoclonal antibodies as possible treatment for COVID-19
Posted Today The National Institutes of Health (NIH) and Operation Warp Speed have chosen a University of Minnesota School of Public Health research team to begin a global clinical trial of synthetic versions of natural human antibodies — called neutralizing monoclonal antibodies — as a treatment for COVID-19. The collaborative study, named ACTIV-3, will investigate...
Post
Evidence lags behind excitement over blood plasma as a coronavirus treatment
Researchers call for more rigorous clinical trials as rumours abound that US regulators are considering widening access to the potential therapy. Plasma is a yellow liquid left behind after cells are removed from donated blood. It contains antibodies and immune-regulating proteins that could help treat disease.Credit: Guillermo Legaria/Getty US President Donald Trump has called on...
Post
Negative side effects of opioids could be coming from users’ own immune systems
by American Chemical Society larger the dose of opioid, the larger the antibody response. “This was surprising,” Kyzer says. “We saw antibody responses in people who were taking large doses for as little as 6 months.” The scientists are now working on isolating the key opioid antigenic intermediates in the body that prompt the generation...
Post
Vaccine developed for human herpesvirus 6B
by Kobe University A research group led by Professor Mori Yasuko (of the Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine) has revealed that the HHV-6B glycoprotein complex gH/gL/gQ1/gQ2 is an effective vaccine candidate for human herpesvirus 6B (HHV-6B). There are still no methods to treat or prevent HHV-6B...
Post
The behaviour of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells. However, in the more than 20 years since their use began, the molecular mechanisms that underlie this therapy are still little understood. For the first time, scientists from the...
Post
The behavior of therapeutic antibodies in immunotherapy
by CNRS Human antigen CD20 molecules (blue and pink) expressed on the surface of B cells are recognised by type 1 (green), and type 2 (orange) therapeutic antibodies. Only type 1 antibodies can potently recruit complement C1 component (light brown) to elicit complement pathway. Credit: Nicolas Reyes Since the late 1990s, immunotherapy has been the...
Post
Preliminary study of 300+ COVID-19 patients suggests convalescent plasma therapy effective
American Journal of Pathology publishes efficacy results from Houston Methodist clinical trial HOUSTON METHODIST HOUSTON METHODIST PHYSICIAN SCIENTIST ERIC SALAZAR, MD, PHD, LOOKS ON AS HIS TEAM WORKS IN THE LAB ON CONVALESCENT PLASMA RESEARCH. view more CREDIT: HOUSTON METHODIST HOUSTON-(Aug. 12, 2020) – A preliminary analysis of an ongoing study of more than 300...